News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
HENGRUI PHARMA's Drugs Receive Approval in CN for Combined Clinical Trials
HENGRUI PHARMA (01276.HK) announced that the group, together with its subsidiaries Suzhou Suncadia Biopharmaceuticals and Shanghai Shengdi Pharmaceutical, has received approval fro...
Reset
Send
The window will close in 5 seconds
HENGRUI PHARMA's Drugs Receive Approval in CN for Combined Clinical Trials
Close
Recommend
4
Positive
7
Negative
2
 
SHORT SELL
 
STOCK INFO

HENGRUI PHARMA (01276.HK)  +0.600 (+1.054%)   announced that the group, together with its subsidiaries Suzhou Suncadia Biopharmaceuticals and Shanghai Shengdi Pharmaceutical, has received approval from China's National Medical Products Administration for the clinical trial applications of SHR-A1811 for injection, Adebrelimab injection, and Famitinib malate capsules.

Clinical trials are set to commence soon.
(HK stocks quote is delayed for at least 15 mins.)

Related NewsCICC: Wave of A-Shrs Listing on H-shr Mkt Continues; ~50 A-Shrs Plan to List in HK Subsequently; Potential Liquidity Demand Expected to Be Max. $180B

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.